A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds

• Main Authors: TIMOTHY MARK WILLSON, ELIZABETH ELLEN SUGG, MILANA DEZUBE, RONALD GEORGE SHERRILL, JERZY RYSZARD SZEWCZYK, CHRISTOPHER JOSEPH AQUINO
• Format: Patent
• Language: English
• Published: 10.11.1995
• Edition: 6
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PCT No. PCT/EP95/01335 Sec. 371 Date Oct. 11, 1996 Sec. 102(e) Date Oct. 11, 1996 PCT Filed Apr. 13, 1995 PCT Pub. No. WO95/28399 PCT Pub. Date Oct. 26, 1995A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), (I) where R1 is C1-C6alkyl, C3-6cycloalkyl, phenyl, or substituted phenyl; R2 is C3-6alkyl, C3-6cycloalkyl, C3-6alkenyl, benzyl, phenylC1-3alkyl or substituted phenyl; or NR1R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C1-6alkyl, C1-6alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0,1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R3, R4, R5 and R8 are selected from a variety of substituents; X is nitrogen, nitroso or R8; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).